Bortezomib and thalidomide for the first‑line treatment of multiple myeloma

  • Technology appraisal guidance
  • TA228
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The assessment report for this appraisal was prepared by Southampton Health Technology Assessment Centre:

  • Picot J, Cooper K, Bryant J, Clegg A et al. Bortezomib and thalidomide for the first-line treatment of multiple myeloma: a multiple technology appraisal (February 2010)

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Manufacturers or sponsors, professional or specialist, patient or carer groups, and other consultees were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • Janssen

  • Celgene

Professional or specialist, and patient or carer groups:

  • Leukaemia CARE

  • Macmillan Cancer Relief

  • Myeloma UK

  • British Society for Haematology

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians, Medical Oncology Joint Special Committee

  • UK Myeloma Forum

Other consultees:

  • Department of Health

  • Hammersmith and Fulham PCT

  • Welsh Assembly Government

Commentator organisations (without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • GlaxoSmithKline

  • Leukaemia Research Fund

  • Medical Research Council Clinical Trials Unit

  • Clinical Trials Research Unit (CTRU), University of Leeds

  • National Institute for Health Research Health Technology Assessment Programme

  • Southampton Health Technology Assessment Centre, University of Southampton

  • National Collaborating Centre for Cancer

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on Bortezomib and Thalidomide for the first-line treatment of multiple myeloma by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Gordon Cooke, nominated by UK Myeloma Forum – clinical specialist

  • Dr Stephen Schey, nominated by NCRI, RCP, RCR, ACP, JCCO, Royal college of Physicians – clinical specialist

  • Dr Kwee Yong, nominated by Royal College of Pathologists and BSH – clinical specialist

  • Eric Low, nominated by Myeloma UK – patient expert

  • Michael Brown, nominated by Myeloma UK – patient expert

Representatives from the following manufacturers or sponsors attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Janssen

  • Celgene